Canada Pension Plan Investment Board, a global investment management organisation, led a $175m Series B round in Asimov, the synthetic biology company building tools to design living systems, with participation from Fidelity Management & Research Company, KDT, Casdin Capital, Pillar, Andreessen Horowitz and Horizons Ventures. "The field of engineered medicines is advancing rapidly. A wave of therapeutics that used to be the stuff of science fiction is now reaching patients. But the technology to design and manufacture these drugs hasn’t kept up. At Asimov we’re integrating synthetic biology and computer-aided design to address the challenges of high manufacturing costs, drug quality, and scalability. We’re energized to partner with such an acclaimed set of investors that shares our vision," Alec Nielsen, Asimov CEO.